A citation-based method for searching scientific literature

Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.
Jeff P Sharman, Andres Forero-Torres, Luciano J Costa, Ian W Flinn, Lowell Inhorn, Kevin Kelly, Alberto Bessudo, Luis E Fayad, Mark S Kaminski, Andrew M Evens, Christopher R Flowers, Deniz Sahin, Kirsten E Mundt, Thomas Sandmann, Günter Fingerle-Rowson, Charlotte Vignal, Mehrdad Mobasher, Andrew D Zelenetz. Leuk Lymphoma 2019
Times Cited: 12



Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL.
Kerry J Savage, Graham W Slack, Anja Mottok, Laurie H Sehn, Diego Villa, Roopesh Kansara, Robert Kridel, Christian Steidl, Daisuke Ennishi, King L Tan, Susana Ben-Neriah, Nathalie A Johnson, Joseph M Connors, Pedro Farinha, David W Scott, Randy D Gascoyne. Blood 2016
Times Cited: 115




List of shared articles



Times cited

Immune targeted therapy for diffuse large B cell lymphoma.
Yaxin Zheng, Junqi Si, Tian Yuan, Sa Ding, Chen Tian. Blood Sci 2021
2

Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP.
Patrizia Mondello, Michael Mian. Hematol Oncol 2019
24


Longstocking, LLC. © 2021
Home | About Us | FAQs | Terms & Privacy